DoH Policies screened during the period: 1st October 2016 to 31st December 2016
Topics:
Date published:
In fulfilling its obligations under Section 75 the Department is required to equality screen all of its policies and services under consideration to determine whether they should be subject to a full equality impact assessment (EQIA).
Documents
- NICE Technology Appraisal - TA407 - Secukinumab for treating ankylosing spondylitis after inadequate response to non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors
- NICE Technology Appraisal TA412 - Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases
- NICE Technology Appraisal TA410 - Talimogene laherparepvec for treating unresectable metastatic melanoma
- NICE Technology Appraisal TA409 - Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion
- NICE Technology Appraisal - TA 406 - Crizotinib for untreated anaplastic lymphoma kinase-positive non-small-cell lung cancer
- NICE Technology Appraisal TA408 - Pegaspargase for treating acute lymphoblastic leukaemia
- NICE Technology Appraisal TA411 - Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer
- NICE Clinical Guideline - NG54 - Mental health problems in people with learning disabilities: prevention, assessment and management
- NICE Public Health Guideline NG48 - Oral health for adults in care homes
- NICE Clinical Guideline - NG56 - Multimorbidity: clinical assessment and management
- NICE Technology Appraisal TA415 - Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor
- NICE Technology Appraisal TA414 - Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma
- NICE Technology Appraisal TA413 Elbasvir–grazoprevir for treating chronic hepatitis C
- NG26 - Children’s attachment: attachment in children and young people who are adopted from care, in care or at high risk of going into care
- NICE Technology Appraisal TA418 - Dapagliflozin in triple therapy for treating type 2 diabetes (part review of TA288)
- NICE Technology Appraisal TA417 - Nivolumab for treated or metastatic renal cell carcinoma
- NICE Technology Appraisal TA419 - Apremilast for treating moderate to severe plaque psoriasis (review of TA368)
- NICE Technology Appraisal TA420 - Ticagrelor for secondary prevention of atherothrombotic events after myocardial infarction
- “The Right Time, The Right Place”: An expert examination of the application of health and social care governance arrangements for ensuring the quality of care provision in Northern Ireland
- Criteria for Reconfiguring Health and Social Care Services